Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
WEB4 days ago · About multiple myeloma MM is the second most common hematologic malignancy 1, affecting more than 130,000 patients in the US; approximately 32,000 Americans are diagnosed with MM each year. 2 Despite available treatments, MM remains an incurable malignancy with an estimated 52% five-year survival rate for newly diagnosed patients. 3 According ...
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB4 days ago · FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. News release. FDA. September 20, 2024. Accessed September 20, 2024.
Multiple Myeloma: Improved Prognosis With the Latest Treatments
WEBAug 16, 2023 · The overall five-year survival rate for people with active multiple myeloma in the United States has increased steadily over time, to more than 55% today. It’s important to remember that even the most recent statistics apply to many people who did not have access to the newer treatments.
Advances in multiple myeloma treatment - Mayo Clinic …
WEBMay 16, 2024 · Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. And as multiple myeloma research continues, a cure may someday be on the horizon.
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and ...
WEB5 days ago · Efficacy was evaluated in IMROZ (NCT03319667), an open-label, randomized, active-controlled phase 3 trial in patients with newly diagnosed multiple myeloma who were not eligible for ASCT.
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard treatment regimen was more effective than that standard regimen on its own.
FDA Approves Two New Treatments for Heavily Pretreated Multiple Myeloma
WEBRye Brook, N.Y., August 16, 2023 – The U.S. Food and Drug Administration (FDA) in August approved both talquetamab-tgvs (Talvey™) and elranatamab (Elrexfio™) to treat adults with multiple myeloma that has failed to respond or …
FDA Approves First Cell-Based Gene Therapy for Adult Patients …
WEBMarch 27, 2021. The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded...
CAR T-Cell Therapy Approved for Multiple Myeloma - NCI
WEBApr 14, 2021 · A type of immunotherapy called CAR T-cell therapy is now an option for some people with multiple myeloma. On March 26, the Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that has not responded to or has returned after at least four different prior cancer treatments.
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma
WEBMar 30, 2022 · On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment (refractory) or has returned after treatment (relapsed).
Skip to content